CPX-351 Plus Ivosidenib

Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
30 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Chemotherapy, Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1557
NCT Identifier
NCT04493164

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.